Author:
Brazier Benedict,McShane Helen
Abstract
AbstractMycobacterium tuberculosis remains the leading cause of death attributed to a single infectious organism. Bacillus Calmette-Guerin (BCG), the standard vaccine against M. tuberculosis, is thought to prevent only 5% of all vaccine-preventable deaths due to tuberculosis, thus an alternative vaccine is required. One of the principal barriers to vaccine development against M. tuberculosis is the complexity of the immune response to infection, with uncertainty as to what constitutes an immunological correlate of protection. In this paper, we seek to give an overview of the immunology of M. tuberculosis infection, and by doing so, investigate possible targets of vaccine development. This encompasses the innate, adaptive, mucosal and humoral immune systems. Though MVA85A did not improve protection compared with BCG alone in a large-scale clinical trial, the correlates of protection this has revealed, in addition to promising results from candidate such as VPM1002, M72/ASO1E and H56:IC31 point to a brighter future in the field of TB vaccine development.
Publisher
Springer Science and Business Media LLC
Subject
Immunology,Immunology and Allergy
Reference245 articles.
1. Global Tuberculosis Report (WHO), (2019) Geneva
2. Keja K, Chan C, Hayden G, Henderson RH (1988) Expanded programme on immunization. World Health Stat Q 41(2):59–63
3. Divangahi M (2018) Are tolerance and training required to end TB? Nat Rev Immunol 18(11):661
4. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV et al (1994) Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA. 271(9):698–702
5. WHO, (2001). Global tuberculosis control. WHO report
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献